文献速递艾滋病与性传播感染

口服利奈唑胺与苄星青霉素G治疗成人早期梅毒的对比(西班牙Trep-AB研究):一项前瞻性、开放标签、非劣效性、随机对照试验

Oral linezolid compared with benzathine penicillin G for treatment of early syphilis in adults (Trep-AB Study) in Spain: a prospective, open-label, non-inferiority, randomised controlled trial.
PubMed 文献 · Lancet Infect Dis · 2024-01-08

在西班牙加泰罗尼亚三个性传播感染诊疗点开展的多中心、开放标签、非劣效性随机对照试验,将59例早期梅毒患者按1:1随机分配至口服利奈唑胺600 mg每日一次共5天组(n=29)或肌内注射苄星青霉素G单剂2.4百万国际单位组(n=30)。符合方案集分析显示,随访48周时利奈唑胺组27例中19例(70%)治疗应答,苄星青霉素G组28例中28例(100%)应答,治疗率差异为-29.6(95%CI -50.5至-8.8),未达到非劣效性标准。作者结论认为该利奈唑胺方案不应被用于治疗早期梅毒患者。

要点

  • 随访48周,利奈唑胺组治疗应答19/27(70%),苄星青霉素G组28/28(100%),差异-29.6(95%CI -50.5至-8.8),未达非劣效。
  • 药物相关不良事件两组相似(利奈唑胺5/29[17%] vs 苄星青霉素G 5/30[17%]),均为轻中度,随访期间未报告严重不良事件。
  • 作者结论:口服利奈唑胺600 mg每日一次共5天不应被用于治疗早期梅毒患者。

核心结论

  • 口服利奈唑胺600 mg每日一次共5天方案与苄星青霉素G相比未达到非劣效性标准,因此该方案不应被用于治疗早期梅毒患者。

研究设计与样本

  • 多中心、开放标签、非劣效性、随机对照试验,在西班牙加泰罗尼亚一个公立医院性传播感染单元和两个社区性传播感染诊所招募经血清学或分子学确诊的早期梅毒(一期、二期或早期潜伏)成人患者。
  • 采用计算机生成的区组随机化列表按1:1比例随机分配,每区组6例,口服利奈唑胺600 mg每日一次共5天或肌内注射苄星青霉素G单剂2.4百万国际单位。
  • 主要终点为治疗应答,采用包含临床应答、血清学应答和无复发的复合终点;非劣效性标准为治疗应答率差异的双侧95%CI下限高于-10%;主要分析在符合方案集进行。
  • 试验在ClinicalTrials.gov注册(NCT05069974),并在中期分析后因无效而停止。

主要发现

  • 2021年10月20日至2022年9月15日期间,62例患者接受资格评估,59例被随机分配至利奈唑胺组(n=29)或苄星青霉素G组(n=30)。
  • 符合方案集随访48周后,利奈唑胺组27例中19例(70%,95%CI 49.8至86.2)治疗应答,苄星青霉素G组28例中28例(100%,95%CI 87.7至100.0)治疗应答,治疗率差异为-29.6(95%CI -50.5至-8.8),未达到非劣效性标准。
  • 药物相关不良事件(均为轻中度)两组相似:利奈唑胺组29例中5例(17%,95%CI 5.8至35.8),苄星青霉素G组30例中5例(17%,95%CI 5.6至34.7)。
  • 随访期间未报告严重不良事件。

关键数值与推荐

  • 血清学治愈定义为12周、24周或48周任一时间点快速血浆反应素滴度下降四倍或血清学转阴。
  • 无复发定义为复发性梅毒中检出不同分子序列型的梅毒螺旋体。
  • 非劣效性界值为治疗应答率差异的双侧95%CI下限高于-10%。

临床怎么用

  • 作者结论认为口服利奈唑胺600 mg每日一次共5天方案不应被用于治疗早期梅毒患者。

局限性

  • 试验在中期分析后因无效而停止。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Management of syphilis, a sexually transmitted infection (STI) with increasing incidence, is challenged by drug shortages, scarcity of randomised trial data, an absence of non-penicillin alternatives for pregnant women with penicillin allergy (other than desensitisation), extended parenteral administration for neurosyphilis and congenital syphilis, and macrolide resistance. Linezolid was shown to be active against Treponema pallidum, the causative agent of syphilis, in vitro and in the rabbit model. We aimed to assess the efficacy of linezolid for treating early syphilis in adults compared with the standard of care benzathine penicillin G (BPG). METHODS: We did a multicentre, open-label, non-inferiority, randomised controlled trial to assess the efficacy of linezolid for treating early syphilis compared with BPG. We recruited participants with serological or molecular confirmation of syphilis (either primary, secondary, or early latent) at one STI unit in a public hospital and two STI community clinics in Catalonia (Spain). Participants were randomly allocated in a 1:1 ratio using a computer-generated block randomisation list with six participants per block, to receive either oral linezolid (600 mg once per day for 5 days) or intramuscular BPG (single dose of 2·4 million international units) and were assessed for signs and symptoms (once per week until week 6 and at week 12, week 24, and week 48) and reagin titres of non-treponemal antibodies (week 12, week 24, and week 48). The primary endpoint was treatment response, assessed using a composite endpoint that included clinical response, serological response, and absence of relapse. Clinical response was assessed at 2 weeks for primary syphilis and at 6 weeks for secondary syphilis following treatment initiation. Serological cure was defined as a four-fold decline in rapid plasma reagin titre or seroreversion at any of the 12-week, 24-week, or 48-week timepoints. The absence of relapse was defined as the presence of different molecular sequence types of T pallidum in recurrent syphilis. Non-inferiority was shown if the lower limit of the two-sided 95% CI for the difference in rates of treatment response was higher than -10%. The primary analysis was done in the per-protocol population. The trial is registered at ClinicalTrials.gov (NCT05069974) and was stopped for futility after interim analysis. FINDINGS: Between Oct 20, 2021, and Sept 15, 2022, 62 patients were assessed for eligibility, and 59 were randomly assigned to linezolid (n=29) or BPG (n=30). In the per-protocol population, after 48 weeks' follow-up, 19 (70%) of 27 participants (95% CI 49·8 to 86·2) in the linezolid group had responded to treatment and 28 (100%) of 28 participants (87·7 to 100·0) in the BPG group (treatment difference -29·6, 95% CI -50·5 to -8·8), which did not meet the non-inferiority criterion. The number of drug-related adverse events (all mild or moderate) was similar in both treatment groups (five [17%] of 29, 95% CI 5·8 to 35·8 in the linezolid group vs five [17%] of 30, 5·6 to 34·7, in the BPG group). No serious adverse events were reported during follow-up. INTERPRETATION: The efficacy of linezolid at a daily dose of 600 mg for 5 days did not meet the non-inferiority criteria compared with BPG and, as a result, this treatment regimen should not be used to treat patients with early syphilis. FUNDING: European Research Council and Fondo de Investigaciones Sanitarias.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Ubals M, Nadal-Baron P, Arando M, et al. Oral linezolid compared with benzathine penicillin G for treatment of early syphilis in adults (Trep-AB Study) in Spain: a prospective, open-label, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2024. PMID: 38211601. doi:10.1016/S1473-3099(23)00683-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。